Phase I study of N-(Phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer

Ronald A. Fleming, Robert L. Capizzi, Hyman B. Muss, Stephen Smith, Daniel J. Fernandes, Howard Homesley, Brian W. Loggie, L. Douglas Case, Reba Morris, Gregory B. Russell, Frederick Richards

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We conducted a combined biochemical modulation trial of N-(phosphonacetyl)-L-aspartate (PALA), dipyridamole (DP), and fluorouracil (5-FU) in patients with cancer. Eighty eight patients with advanced cancer were entered into this Phase I trial. During the first part of the study, four doses of PALA (125, 250, 500, and 1000 mg/m2, administered on day 1) were evaluated to determine the PALA dose with maximal suppression of aspartate transcarbamylase (ATCase) activity that was clinically tolerable. Patients were randomized to receive DP (or no DP), 50 mg/m2, p.o. every 6 h on days 1-6, and all patients received 5-FU, 400 mg/m2, by bolus administration on days 25. Prior to and during therapy. WBCs were collected and assayed for ATCase activity. After the maximally tolerated PALA dose with 400 mg/2 5-FU ± 50 mg/m2 DP was defined, the 5-FU dose was escalated using the same administration schedule of 5-FU, PALA, and DP. The dose of 5-FU was escalated by 25% in each of the DP cohorts until dose-limiting toxicity was reached. ATCase activity was inhibited in a dose-dependent manner with PALA doses of 125, 250, 500, and 1000 mg/m2, resulting in 0, 13, 17, and 49% inhibition of ATCase activity. Only at the higher PALA doses (i.e., 500 and 1000 mg/m2) was ATCase activity suppressed during days 2-5, but the activity returned to pretreatment levels by day 15. Based on the clinical tolerance and significant suppression of ATCase activity, a PALA dose of 500 mg/m2 was selected for the 5-FU dose escalation phase. At a 5-FU dose of 625 mg/m2, dose-limiting toxicity (leukopenia, stomatitis, and diarrhea) occurred in both DP cohorts. We recommend that for this monthly treatment schedule, 500 mg/m2 PALA and 500 mg/m2 5-FU, with or without 50 mg/m2 DP, be used in subsequent Phase II trials.

Original languageEnglish
Pages (from-to)1107-1114
Number of pages8
JournalClinical Cancer Research
Volume2
Issue number7
StatePublished - Jul 1996
Externally publishedYes

Fingerprint

NSC 224131
Dipyridamole
Fluorouracil
Aspartate Carbamoyltransferase
Aspartic Acid
Neoplasms
Appointments and Schedules
Stomatitis
Leukopenia

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Fleming, R. A., Capizzi, R. L., Muss, H. B., Smith, S., Fernandes, D. J., Homesley, H., ... Richards, F. (1996). Phase I study of N-(Phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. Clinical Cancer Research, 2(7), 1107-1114.

Phase I study of N-(Phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. / Fleming, Ronald A.; Capizzi, Robert L.; Muss, Hyman B.; Smith, Stephen; Fernandes, Daniel J.; Homesley, Howard; Loggie, Brian W.; Case, L. Douglas; Morris, Reba; Russell, Gregory B.; Richards, Frederick.

In: Clinical Cancer Research, Vol. 2, No. 7, 07.1996, p. 1107-1114.

Research output: Contribution to journalArticle

Fleming, RA, Capizzi, RL, Muss, HB, Smith, S, Fernandes, DJ, Homesley, H, Loggie, BW, Case, LD, Morris, R, Russell, GB & Richards, F 1996, 'Phase I study of N-(Phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer', Clinical Cancer Research, vol. 2, no. 7, pp. 1107-1114.
Fleming, Ronald A. ; Capizzi, Robert L. ; Muss, Hyman B. ; Smith, Stephen ; Fernandes, Daniel J. ; Homesley, Howard ; Loggie, Brian W. ; Case, L. Douglas ; Morris, Reba ; Russell, Gregory B. ; Richards, Frederick. / Phase I study of N-(Phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 7. pp. 1107-1114.
@article{d2fc2ef5c738443d877a4ce8443e6dde,
title = "Phase I study of N-(Phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer",
abstract = "We conducted a combined biochemical modulation trial of N-(phosphonacetyl)-L-aspartate (PALA), dipyridamole (DP), and fluorouracil (5-FU) in patients with cancer. Eighty eight patients with advanced cancer were entered into this Phase I trial. During the first part of the study, four doses of PALA (125, 250, 500, and 1000 mg/m2, administered on day 1) were evaluated to determine the PALA dose with maximal suppression of aspartate transcarbamylase (ATCase) activity that was clinically tolerable. Patients were randomized to receive DP (or no DP), 50 mg/m2, p.o. every 6 h on days 1-6, and all patients received 5-FU, 400 mg/m2, by bolus administration on days 25. Prior to and during therapy. WBCs were collected and assayed for ATCase activity. After the maximally tolerated PALA dose with 400 mg/2 5-FU ± 50 mg/m2 DP was defined, the 5-FU dose was escalated using the same administration schedule of 5-FU, PALA, and DP. The dose of 5-FU was escalated by 25{\%} in each of the DP cohorts until dose-limiting toxicity was reached. ATCase activity was inhibited in a dose-dependent manner with PALA doses of 125, 250, 500, and 1000 mg/m2, resulting in 0, 13, 17, and 49{\%} inhibition of ATCase activity. Only at the higher PALA doses (i.e., 500 and 1000 mg/m2) was ATCase activity suppressed during days 2-5, but the activity returned to pretreatment levels by day 15. Based on the clinical tolerance and significant suppression of ATCase activity, a PALA dose of 500 mg/m2 was selected for the 5-FU dose escalation phase. At a 5-FU dose of 625 mg/m2, dose-limiting toxicity (leukopenia, stomatitis, and diarrhea) occurred in both DP cohorts. We recommend that for this monthly treatment schedule, 500 mg/m2 PALA and 500 mg/m2 5-FU, with or without 50 mg/m2 DP, be used in subsequent Phase II trials.",
author = "Fleming, {Ronald A.} and Capizzi, {Robert L.} and Muss, {Hyman B.} and Stephen Smith and Fernandes, {Daniel J.} and Howard Homesley and Loggie, {Brian W.} and Case, {L. Douglas} and Reba Morris and Russell, {Gregory B.} and Frederick Richards",
year = "1996",
month = "7",
language = "English",
volume = "2",
pages = "1107--1114",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Phase I study of N-(Phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer

AU - Fleming, Ronald A.

AU - Capizzi, Robert L.

AU - Muss, Hyman B.

AU - Smith, Stephen

AU - Fernandes, Daniel J.

AU - Homesley, Howard

AU - Loggie, Brian W.

AU - Case, L. Douglas

AU - Morris, Reba

AU - Russell, Gregory B.

AU - Richards, Frederick

PY - 1996/7

Y1 - 1996/7

N2 - We conducted a combined biochemical modulation trial of N-(phosphonacetyl)-L-aspartate (PALA), dipyridamole (DP), and fluorouracil (5-FU) in patients with cancer. Eighty eight patients with advanced cancer were entered into this Phase I trial. During the first part of the study, four doses of PALA (125, 250, 500, and 1000 mg/m2, administered on day 1) were evaluated to determine the PALA dose with maximal suppression of aspartate transcarbamylase (ATCase) activity that was clinically tolerable. Patients were randomized to receive DP (or no DP), 50 mg/m2, p.o. every 6 h on days 1-6, and all patients received 5-FU, 400 mg/m2, by bolus administration on days 25. Prior to and during therapy. WBCs were collected and assayed for ATCase activity. After the maximally tolerated PALA dose with 400 mg/2 5-FU ± 50 mg/m2 DP was defined, the 5-FU dose was escalated using the same administration schedule of 5-FU, PALA, and DP. The dose of 5-FU was escalated by 25% in each of the DP cohorts until dose-limiting toxicity was reached. ATCase activity was inhibited in a dose-dependent manner with PALA doses of 125, 250, 500, and 1000 mg/m2, resulting in 0, 13, 17, and 49% inhibition of ATCase activity. Only at the higher PALA doses (i.e., 500 and 1000 mg/m2) was ATCase activity suppressed during days 2-5, but the activity returned to pretreatment levels by day 15. Based on the clinical tolerance and significant suppression of ATCase activity, a PALA dose of 500 mg/m2 was selected for the 5-FU dose escalation phase. At a 5-FU dose of 625 mg/m2, dose-limiting toxicity (leukopenia, stomatitis, and diarrhea) occurred in both DP cohorts. We recommend that for this monthly treatment schedule, 500 mg/m2 PALA and 500 mg/m2 5-FU, with or without 50 mg/m2 DP, be used in subsequent Phase II trials.

AB - We conducted a combined biochemical modulation trial of N-(phosphonacetyl)-L-aspartate (PALA), dipyridamole (DP), and fluorouracil (5-FU) in patients with cancer. Eighty eight patients with advanced cancer were entered into this Phase I trial. During the first part of the study, four doses of PALA (125, 250, 500, and 1000 mg/m2, administered on day 1) were evaluated to determine the PALA dose with maximal suppression of aspartate transcarbamylase (ATCase) activity that was clinically tolerable. Patients were randomized to receive DP (or no DP), 50 mg/m2, p.o. every 6 h on days 1-6, and all patients received 5-FU, 400 mg/m2, by bolus administration on days 25. Prior to and during therapy. WBCs were collected and assayed for ATCase activity. After the maximally tolerated PALA dose with 400 mg/2 5-FU ± 50 mg/m2 DP was defined, the 5-FU dose was escalated using the same administration schedule of 5-FU, PALA, and DP. The dose of 5-FU was escalated by 25% in each of the DP cohorts until dose-limiting toxicity was reached. ATCase activity was inhibited in a dose-dependent manner with PALA doses of 125, 250, 500, and 1000 mg/m2, resulting in 0, 13, 17, and 49% inhibition of ATCase activity. Only at the higher PALA doses (i.e., 500 and 1000 mg/m2) was ATCase activity suppressed during days 2-5, but the activity returned to pretreatment levels by day 15. Based on the clinical tolerance and significant suppression of ATCase activity, a PALA dose of 500 mg/m2 was selected for the 5-FU dose escalation phase. At a 5-FU dose of 625 mg/m2, dose-limiting toxicity (leukopenia, stomatitis, and diarrhea) occurred in both DP cohorts. We recommend that for this monthly treatment schedule, 500 mg/m2 PALA and 500 mg/m2 5-FU, with or without 50 mg/m2 DP, be used in subsequent Phase II trials.

UR - http://www.scopus.com/inward/record.url?scp=8944261600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944261600&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 1107

EP - 1114

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -